Our Products:
The company’s innovative BrainScope is an easy-to-use, non-invasive, hand-held platform that empowers physicians to make more accurate TBI assessments quickly and at the point-of-care. BrainScope’s unique system leverages advanced digital signal processing, sophisticated algorithms and machine learning technologies to identify and evaluate key brain electrical activity biomarkers of TBI. BrainScope also includes digitized versions of standard clinical assessments for milder forms of TBI known as concussion.
BrainScope’s unique system leverages advanced digital signal processing, sophisticated algorithms and machine learning technologies to identify and evaluate key brain electrical activity biomarkers of TBI.
BrainScope
Profile:
BrainScope is a medical neurotechnology company that is improving brain health by providing objective, diagnostic insights that enable better patient care.
BrainScope’s advanced digital signal processing of EEG data and AI, machine learning derived algorithms empower physicians to objectively assess head injured patients for both structural and functional mild traumatic brain injuries (mTBI) in under 20 minutes. BrainScope enables emergency physicians to triage mTBI at the point of care without radiation and with a 31% demonstrated potential reduction in unnecessary head CTs. The device is the only FDA-cleared, comprehensive, rapid, and radiation-free assessment of brain bleed and concussion.
The BrainScope Structural Injury Classifier (SIC) indicates the likelihood that the patient would be CT-negative or CT-positive. Sensitivity to even the smallest amount of detectable blood (>1 mL) is 99%, with a negative predictive value (NPV) of 98%. False negatives in the FDA validation study were 2%, none of which were clinically significant, required neurosurgery, or returned to the hospital within 96 hours, and all were GCS 15. In a recent publication using the SIC in the emergency department, there was 100% sensitivity, and no false negatives were reported.
The BrainScope Brain Function Index (BFI) provides an objective marker of brain function impairment that scales with severity of functional impairment and that enables timely informed referrals and continuity of care and may lead to improved patient outcome, satisfaction, MIPS compliance, and HCAHP survey results.
The BrainScope Concussion Index (CI) provides an objective measure to aid in the evaluation of concussion and can be used to assess patients over time—at baseline, time of injury, and recovery time points to aid the physician to make decisions about the patient’s readiness to return to activity.
Intended patient population:
Structural Injury Classifier and Brain Function Index:
- Ages 18 – 85 years
- Glasgow Coma Scale (GCS) 13 – 15
- Within 72 hours of injury.
Suitable for alcohol/drug impaired & patients on blood thinners
Digitized PECARN CT Decision Rule:
- GCS 14-15, 2-17 years of age, within 24 hours
Concussion Index:
- Ages 13-25 years
- GCS 15
- Can be used at baseline, within 72 hours of injury, and throughout time of recovery.
For a complete list of indications, please visit www.brainscope.com.
Contact BrainScope:
Video: